S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
NASDAQ:REPL

Replimune Group - REPL Stock Forecast, Price & News

$19.95
-0.32 (-1.58%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$19.49
$20.68
50-Day Range
$14.20
$21.15
52-Week Range
$13.05
$35.93
Volume
222,092 shs
Average Volume
316,329 shs
Market Capitalization
$983.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.00

Replimune Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
130.6% Upside
$46.00 Price Target
Short Interest
Bearish
6.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
-0.65mentions of Replimune Group in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$334,096 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.63) to ($2.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

242nd out of 1,108 stocks

Biological Products, Except Diagnostic Industry

37th out of 175 stocks

REPL stock logo

About Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Replimune Group Price Performance

Replimune Group stock traded down $0.21 during mid-day trading on Tuesday, reaching $20.06. 4,885 shares of the company's stock were exchanged, compared to its average volume of 159,929. The business's fifty day simple moving average is $18.14 and its 200 day simple moving average is $17.30. Replimune Group has a one year low of $13.05 and a one year high of $35.93. The company has a debt-to-equity ratio of 0.06, a quick ratio of 19.46 and a current ratio of 19.46.

Replimune Group (NASDAQ:REPL - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.15). On average, analysts predict that Replimune Group will post -2.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

REPL has been the topic of a number of recent research reports. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Replimune Group in a report on Tuesday, May 24th. SVB Leerink dropped their target price on Replimune Group from $48.00 to $37.00 and set an "outperform" rating on the stock in a report on Friday. Wedbush dropped their target price on Replimune Group from $59.00 to $52.00 and set an "outperform" rating on the stock in a report on Tuesday, May 24th. Finally, Piper Sandler dropped their target price on Replimune Group from $52.00 to $44.00 in a report on Thursday, May 19th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $46.00.

Insiders Place Their Bets

In other Replimune Group news, CEO Philip Astley-Sparke sold 9,632 shares of the firm's stock in a transaction on Monday, May 16th. The stock was sold at an average price of $14.59, for a total value of $140,530.88. Following the completion of the sale, the chief executive officer now directly owns 1,401,080 shares of the company's stock, valued at $20,441,757.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Pamela Esposito sold 3,507 shares of Replimune Group stock in a transaction on Monday, May 16th. The stock was sold at an average price of $14.59, for a total value of $51,167.13. Following the completion of the transaction, the insider now directly owns 229,402 shares in the company, valued at $3,346,975.18. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Philip Astley-Sparke sold 9,632 shares of Replimune Group stock in a transaction on Monday, May 16th. The shares were sold at an average price of $14.59, for a total value of $140,530.88. Following the completion of the transaction, the chief executive officer now owns 1,401,080 shares of the company's stock, valued at $20,441,757.20. The disclosure for this sale can be found here. Insiders sold 22,899 shares of company stock valued at $334,096 over the last ninety days. 23.80% of the stock is currently owned by insiders.

Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Stock News Headlines

Replimune Group (NASDAQ:REPL) PT Lowered to $37.00
Is Replimune Group (NASDAQ:REPL) Using Too Much Debt?
Replimune Group (NASDAQ:REPL) Stock Price Down 4%
Replimune Group, Inc. (REPL)
Analyst Ratings for Replimune Group
Replimune Group: Q3 Earnings Insights
Replimune Group, Inc. Common Stock (REPL)
See More Headlines
Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Company Calendar

Last Earnings
8/04/2022
Today
8/10/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:REPL
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.00
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+130.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-118,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.71 per share

Miscellaneous

Free Float
37,572,000
Market Cap
$983.67 million
Optionable
Not Optionable
Beta
1.98

Key Executives

  • Mr. Philip Astley-Sparke FSA (Age 51)
    CEO & Director
    Comp: $880.5k
  • Dr. Robert Coffin Ph.D. (Age 57)
    Founder, Pres, Chief R&D Officer and Director
    Comp: $785.89k
  • Ms. Tanya N. Lewis M.S. (Age 51)
    Chief Devel. Operations Officer
    Comp: $4.7k
  • Mr. Sushil Patel Ph.D. (Age 51)
    Chief Commercial Officer
    Comp: $594.58k
  • Ms. Jean M. Franchi (Age 56)
    Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer
  • Dr. Colin A. Love Ph.D. (Age 64)
    Chief Operating Officer
  • Dr. Pamela Esposito Ph.D. (Age 47)
    Chief Bus. Officer













REPL Stock - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REPL shares.
View REPL analyst ratings
or view top-rated stocks.

What is Replimune Group's stock price forecast for 2022?

7 brokerages have issued 12-month price targets for Replimune Group's stock. Their REPL share price forecasts range from $30.00 to $60.00. On average, they expect the company's stock price to reach $46.00 in the next twelve months. This suggests a possible upside of 130.6% from the stock's current price.
View analysts price targets for REPL
or view top-rated stocks among Wall Street analysts.

How has Replimune Group's stock performed in 2022?

Replimune Group's stock was trading at $27.10 at the start of the year. Since then, REPL shares have decreased by 26.4% and is now trading at $19.95.
View the best growth stocks for 2022 here
.

When is Replimune Group's next earnings date?

Replimune Group is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our REPL earnings forecast
.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) released its earnings results on Thursday, August, 4th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.15.

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Emerald Advisers LLC (2.23%), Integral Health Asset Management LLC (0.44%), TD Asset Management Inc. (0.21%), Swiss National Bank (0.11%), SG Americas Securities LLC (0.07%) and Harbor Capital Advisors Inc. (0.06%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends
.

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $19.95.

How much money does Replimune Group make?

Replimune Group (NASDAQ:REPL) has a market capitalization of $983.67 million. The company earns $-118,040,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis.

How many employees does Replimune Group have?

Replimune Group employs 152 workers across the globe.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com.

This page (NASDAQ:REPL) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.